Dex is a highly selective α2‐AR agonist, yielding an α2/α1 ratio of 1620.14 Since utilization of Dex in BC surgeries significantly increases the ratio of patients discharged on the same day, reduces the postoperative consumption of analgesia, and downregulates postoperative side effects, such as nausea, vomiting, and bleeding,15, 16 it is now widely used in BC surgical patients. This evidence concerns the gene ADORA2A and breast cancer.